PR
Prothena Corporation plc
PRTA · NASDAQ
$8.38 -4.66% (-$0.41)
1M -12.80%
Market Cap $438.7M
P/E Ratio -
Div. Yield -
ROE 14.98%
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
3/9Valuation
52 /100
Fair P/B 1.53x
P/S 8.05x
PEG N/A
Growth
0 /100
Declining Book val. growth 23.32%
Rev. growth 43.57%
FCF growth N/A
Profitability
17 /100
Weak FCF margin 111.34%
Op. margin 115.09%
Gross margin 43.52%
Quality
2 /100
Poor Asset turnover 0.18x
ROA 14.54%
ROIC 21.54%
Debt
100 /100
Low Current ratio 25.05x
Debt/Equity 0.02x
Net debt/EBITDA N/A
Stability
20 /100
Unstable Profitable years 0
EPS volatility 61.03%
Beta -0.33x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about PRTA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Gene G. Kinney
Employees
67
Headquarters
Dublin
Upcoming events
05 NOV
Earnings
Upcoming earnings report